Dechert advised CTRS on the deal. CTRS, a French pharmaceutical company which specializes in rare diseases, executed its OBO transaction in which Mérieux Equity Partners, a…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
